Low-grade gliomas

CONTINUUM Lifelong Learning in Neurology

Volumn 21, Issue 2, 2015, Pages 345-354

  Schiff, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; DACARBAZINE;

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; GENE MUTATION; GLIOMA; HUMAN; MEDICAL DECISION MAKING; MOLECULAR PATHOLOGY; NEUROPATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; DISEASE COURSE; GENETICS; MULTIMODALITY CANCER THERAPY; MUTATION; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE PROGRESSION; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; LOMUSTINE; MUTATION; PROCARBAZINE; TREATMENT OUTCOME; VINCRISTINE;

EID: 84926484600     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000464174.88687.79     Document Type: Review

References (34)

1. Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up atMayo Clinic. Neuro Oncol 2009;11(4):437-445. doi:10. 1215/15228517-2008-102.
2. Ricard D, Kaloshi G, Amiel-Benouaich A, et al. Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol 2007;61(5):484-490. doi:10. 1002/ana. 21125.
3. Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA 2012;308(18):1881-1888. doi:10. 1001/jama. 2012. 12807.
4. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 2008;26(8):1338-1345. doi:10. 1200/JCO. 2007. 13. 9337.
5. McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-707. doi:10. 1227/01. NEU. 0000325729. 41085. 73.
6. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002;20(8):2076-2084. doi:10. 1200/JCO. 2002. 08. 121.
7. Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol 2001;3(3):193-200. doi:10. 1093/neuonc/3. 3. 193.
8. Muragaki Y, Chernov M, Maruyama T, et al. Low-grade glioma on stereotactic biopsy: How often is the diagnosis accurate? Minim Invasive Neurosurg 2008;51(5):275-279. doi:10. 1055/s-0028-1082322.
9. Pouratian N, Asthagiri A, Jagannathan J, et al. Surgery insight: The role of surgery in the management of low-grade gliomas. Nat Clin Pract Neurol 2007;3(11):628-639. doi:10. 1038/ncpneuro0634.
10. van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: A clinician's perspective. Acta Neuropathol 2010;120(3):297-304. doi:10. 1007/s00401-010-0725-7.
11. Bourne TD, Schiff D. Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol 2010;6(12):695-701. doi:10. 1038/nrneurol. 2010. 159.
12. Schiff D, Brown PD, Giannini C. Outcome in adult low-grade glioma: The impact of prognostic factors and treatment. Neurology 2007;69(13):1366-1373. doi:10. 1212/01. wnl. 0000277271. 47601. a1.
13. Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008;116(6):597-602. doi:10. 1007/s00401-008-0455-2.
14. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360(8):765-773. doi:10. 1056/NEJMoa0808710.
15. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462(7274):739-744. doi:10. 1038/nature08617.
16. Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010;75(17):1560-1566. doi:10. 1212/WNL. 0b013e3181f96282.
17. Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg 2008;109(5):835-841. doi:10. 3171/JNS/2008/109/11/0835.
18. Nicolasjilwan M, Lopes MB, Larner J, et al. Subependymal seeding of low-grade oligodendroglial neoplasms: A case series. J Neurooncol 2012;108(1):99-108. doi:10. 1007/s11060-012-0800-0.
19. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002;20(9):2267-2276. doi:10. 1200/JCO. 2002. 09. 126.
20. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 1996;36(3):549-556.
21. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: The EORTC 22845 randomised trial. Lancet 2005;366(9490):985-990. doi:10. 1016/S0140-6736(05)67070-5.
22. van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group): Assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 2011;12(6):583-593. doi:10. 1016/S1470-2045(11)70057-2.
23. Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: A comparative study. Lancet 2002;360(9343):1361-1368. doi:10. 1016/S0140-6736(02)11398-5.
24. Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 2009;8(9):810-818. doi:10. 1016/S1474-4422(09)70204-2.
25. Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 2006; 106(8):1759-1765. doi:10. 1002/cncr. 21809.
26. Pouratian N, Gasco J, Sherman JH, et al. Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J Neurooncol 2007;82(3): 281-288. doi:10. 1007/s11060-006-9280-4.
27. Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 2003;14(12):1715-1721. doi:10. 1093/annonc. mdg371.
28. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138. doi:10. 1200/JCO. 2004. 10. 169.
29. Baumert BG, Mason WP, Ryan G, et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033). meetinglibrary. asco. org/content/111001-132. Accessed January 28, 2015.
30. Fisher BG, Lui J, MacDonald DR, et al. A phase II study of a temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas: preliminary results of RTOG 0424. meetinglibrary. asco. org/content/109801-132. Accessed January 28, 2015.
31. Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol 2012;30(25):3065-3070. doi:10. 1200/JCO. 2011. 35. 8598.
32. Buckner JC, Pugh SL, Shaw EG, et al. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. meetinglibrary. asco. org/content/127483-144. Accessed January 28, 2015.
33. Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014;343(6167):189-193. doi:10. 1126/science. 1239947.
34. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006;66(20):9852-9861. doi:10. 1158/0008-5472. CAN-06-1796.